title: Research gaps in pancreatic cancer research and comparative effectiveness research methodologies.
abstract: Despite advances in cancer care, pancreatic adenocarcinoma remains one of the most lethal tumors. Most patients with pancreatic cancer are diagnosed with late stage disease, and approximately 6 % of patients are alive 5 years after diagnosis. Of the 10-20 % of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25 % (Lim et al. in Annals of surgery 237(1):74-85, 2003 [1]; Trede et al. in Annals of surgery 211(4):447-458, 1990 [2]; Crist et al. in Annals of surgery 206(3):358-365, 1987 [3]). Clearly, there is a need to improve the management of this disease. To identify gaps in research and formulate strategies to address these issues, we designed a framework to encompass the scope of research for pancreatic cancer. In this chapter, we will examine each topic heading within this framework for gaps in knowledge and present research strategies focusing on diverse comparative effectiveness research (CER) methodologies to address the identified gaps.
authors: Departments of Surgery and Epidemiology, Albert Einstein College of Medicine, Bronx, NY, USA, Haejin.In@einstein.yu.edu.
authors: Haejin
authors: H
authors: In
authors: Mitchell C
authors: MC
authors: Posner
mesh_terms: D057186:Comparative Effectiveness Research / Q000379:methods*; D004358:Drug Therapy / Q000379:methods; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use; D010185:Pancreatic Fistula / Q000517:prevention & control; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D016577:Pancreaticoduodenectomy; D011182:Postoperative Care; D057170:Translational Research, Biomedical
chemical_list: D015282:Octreotide